Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis.
about
Review article: anti-adhesion therapies for inflammatory bowel diseaseMeta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis.Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis.Antisense approach to inflammatory bowel disease: prospects and challenges.Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease.Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.Carrier-free Gene Silencing by Amphiphilic Nucleic Acid Conjugates in Differentiated Intestinal Cells.Colonic treatments and targets: issues and opportunities.Anti-adhesion molecule therapy for inflammatory bowel diseaseTopical therapies in inflammatory bowel disease.Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease.Review article: strategies for the management of chronic unremitting ulcerative colitis.Targeting integrins and adhesion molecules to combat inflammatory bowel disease.MicroRNAs in inflammatory bowel diseases: paradoxes and possibilities.Systematic Review: Rectal Therapies for the Treatment of Distal Forms of Ulcerative Colitis.Current and Future Targets for Mucosal Healing in Inflammatory Bowel Disease.Alicaforsen for the treatment of inflammatory bowel disease.Alicaforsen: An Emerging Therapeutic Agent for Ulcerative Colitis and Refractory Pouchitis.Emerging drugs to treat Crohn's disease.Assessment of the effects of ISIS 2302, an anti-sense inhibitor of human ICAM-1, on cellular and humoral immunity in mice.Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis.Alicaforsen in the treatment of pouchitis.Ultrasound-Mediated Delivery of RNA to Colonic Mucosa of Live Mice.
P2860
Q26999705-60871888-9262-40A3-8827-3F1B924E052EQ30644152-9CA289B4-26A6-447C-880D-9C1F234B63FCQ34243433-0C1906D0-4136-496D-BFD6-7469DC453FD5Q34473572-11CFE7F9-A4DA-4EF0-8F32-B0565F563E81Q37188711-751AB32F-73DD-45FE-A4AE-2A4244C2F9F1Q37321859-DF771C90-80EA-4F63-8343-385EEDACD4B4Q37325084-1B5F2BC9-B00A-4999-AAD6-B2F843685052Q37530912-B323D60B-8A46-4F49-BE91-C25D9A341B58Q37823325-5F98B8B0-BDD4-4CF1-A49F-A9460086D634Q38050885-CDB29D3B-F282-4966-B06C-5B35CBEA3EA0Q38053495-E1661C73-A5EC-43AB-8CC5-B665B6C26FB3Q38110317-5E87C82F-13B3-48E3-9FA9-B60CE1343F18Q38248635-6432609D-F80C-4196-A9E1-1A6C8D5EB41AQ38407040-B76DC25E-12C3-4749-9B52-D88F3BD71153Q38505808-EC68711E-589F-4CCF-A4F9-8106CA77CC3FQ38671272-B6EDD078-4341-40B7-8FCD-56A780AE66C9Q38697244-7B1B8FEF-2282-4F4F-9910-35852D14BD88Q38992068-3B076E07-79F3-42B0-9F25-8C02F035A0EBQ39881787-15AB9936-6D13-49AC-9C7D-0193090A3010Q46092877-5809D932-FB12-4DDE-A526-616A9449947AQ47365129-99FD43CC-CF87-4798-884B-C4DBD3BCF948Q48567953-26F9C2CA-36D7-465F-AB57-D07C0ED17EB8Q51044431-7B075CD3-DDF1-469A-996E-EE92D753C63E
P2860
Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Bioavailability and therapeuti ...... ith active ulcerative colitis.
@en
Bioavailability and therapeutic activity of alicaforsen
@nl
type
label
Bioavailability and therapeuti ...... ith active ulcerative colitis.
@en
Bioavailability and therapeutic activity of alicaforsen
@nl
prefLabel
Bioavailability and therapeuti ...... ith active ulcerative colitis.
@en
Bioavailability and therapeutic activity of alicaforsen
@nl
P2093
P2860
P1476
Bioavailability and therapeuti ...... ith active ulcerative colitis.
@en
P2093
Miner PB Jr
P2860
P304
P356
10.1111/J.1365-2036.2006.02909.X
P407
P577
2006-05-01T00:00:00Z